Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Healthtrust
US Army
Moodys
Boehringer Ingelheim
Queensland Health
Cipla
Colorcon
Julphar

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TECHNETIUM TC-99M SESTAMIBI

« Back to Dashboard

Clinical Trials for Technetium Tc-99m Sestamibi

Trial ID Title Status Sponsor Phase Summary
NCT00162045 A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Completed Lantheus Medical Imaging Phase 1/Phase 2 The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.
NCT00162071 A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging Terminated Forest Laboratories Phase 2 The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
NCT00560495 Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer Withdrawn National Cancer Institute (NCI) Phase 1 RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00560495 Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer Withdrawn Roswell Park Cancer Institute Phase 1 RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00767468 Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis Terminated National Cancer Institute (NCI) Phase 1 RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Technetium Tc-99m Sestamibi

Condition Name

Condition Name for Technetium Tc-99m Sestamibi
Intervention Trials
Liver Cancer 1
Kawasaki Disease 1
Ischemic Heart Disease 1
Constipation-predominant Irritable Bowel Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Technetium Tc-99m Sestamibi
Intervention Trials
Syndrome 2
Mucocutaneous Lymph Node Syndrome 1
Lung Neoplasms 1
Short Bowel Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Technetium Tc-99m Sestamibi

Trials by Country

Trials by Country for Technetium Tc-99m Sestamibi
Location Trials
United States 12
Taiwan 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Technetium Tc-99m Sestamibi
Location Trials
Minnesota 2
New York 2
Hawaii 1
Florida 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Technetium Tc-99m Sestamibi

Clinical Trial Phase

Clinical Trial Phase for Technetium Tc-99m Sestamibi
Clinical Trial Phase Trials
Phase 4 1
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Technetium Tc-99m Sestamibi
Clinical Trial Phase Trials
Completed 3
Terminated 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Technetium Tc-99m Sestamibi

Sponsor Name

Sponsor Name for Technetium Tc-99m Sestamibi
Sponsor Trials
National Cancer Institute (NCI) 2
Mayo Clinic 2
Lantheus Medical Imaging 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Technetium Tc-99m Sestamibi
Sponsor Trials
Other 4
NIH 4
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Covington
Daiichi Sankyo
Merck
Dow
US Army
Julphar
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.